(S)-3-hydroxybutyl-triphenylphosphonium iodide | 59780-25-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-3-hydroxybutyl-triphenylphosphonium iodide
• 英文别名: 3-hydroxybutyltriphenylphosphonium iodide；(3S)-3-hydroxybutyl-triphenylphosphonium iodide；(3S)-hydroxybutyl-triphenylphosphonium iodide；[(3S)-3-hydroxybutyl]-triphenylphosphanium;iodide
• CAS: 59780-25-5
• 化学式: C₂₂H₂₄OP*I
• 分子量: 462.31
• InChiKey: DWRHPZBSAXQQOK-FYZYNONXSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.76
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-3-hydroxybutyl-triphenylphosphonium iodide 在 正丁基锂 作用下， 生成 (S)-4-(Triphenyl-λ⁵-phosphanylidene)-butan-2-ol anion
  参考文献：
  名称：

  Yamamoto, Shin-ichi; Takeuchi, Hiroshi; Tanaka, Yuichiro, Chemistry Letters, 1991, # 1, p. 113 - 116

  摘要：

  DOI：
• 作为产物：
  描述：

  (3S)-1-iodo-3-triethylsilyloxy-butane 、 三苯基膦 以 乙腈 为溶剂， 反应 2.0h， 以87%的产率得到(S)-3-hydroxybutyl-triphenylphosphonium iodide
  参考文献：
  名称：

  2-Methylene-(20S,25S)-19,26-Dinor-Vitamin D Analogs

  摘要：

  这项发明披露了2-亚甲基-(20S,25S)-19,26-二诺尔维生素D类似物，具体为2-亚甲基-(20S,25S)-19,26-二诺尔-1α,25-二羟基维生素D3，以及其药用。该化合物在阻止未分化细胞增殖和诱导它们向单核细胞分化方面表现出显著活性，因此可作为抗癌剂以及用于治疗银屑病等皮肤疾病以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况的药物。该化合物在钙代谢方面几乎没有活性，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及肾性骨病。此外，该化合物还可用于肥胖的治疗或预防。

  公开号：

  US20090170821A1

文献信息

• Synthese des (<i>R</i>)-<i>trans</i>-11-Hydroxy-8-dodecensäure-lactons (Recieifeiolid)
  作者：Hans Gerlach、Konrad Oertle、Adolf Thalmann

  DOI：10.1002/hlca.19760590306

  日期：1976.4.21

  Synthesis of Recifeiolide

  雷西福利内酯的合成
• 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses
  申请人：DeLuca Hector F.

  公开号：US20120283228A1

  公开（公告）日：2012-11-08

  This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D 3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds have little, if any, in vivo calcemic activity and therefore may be used to treat autoimmune disorders in humans as well as secondary hyperparathyroidism and renal osteodystrophy.

  这项发明揭示了19,26-去甲基-1α,25-二羟基维生素D3的2α-甲基和2β-甲基类似物以及其药用。这些化合物在体外表现出生物活性，可作为抗癌剂以及治疗银屑病等皮肤疾病，以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况的用途。这些化合物在体内几乎没有钙调节活性，因此可用于治疗人类的自身免疫性疾病，以及继发性甲状旁腺功能亢进和肾性骨病。
• VITAMIN D ANALOG - NEL, METHODS AND USES THEREOF
  申请人：DELUCA Hector F.

  公开号：US20070191316A1

  公开（公告）日：2007-08-16

  Compounds of formula IA or IB are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups and R 1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to 8 carbon atoms; straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms; straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

  提供了公式为IA或IB的化合物，其中X1、X2和X3独立地选自H或羟基保护基团，R1选自直链或支链烷基，其碳原子数为1至8；直链或支链烯基，其碳原子数为2至8；直链或支链羟基取代的烷基，其碳原子数为1至8；直链和支链羟基取代的烯基，其碳原子数为2至8。这些化合物用于制备药物组合物，并且在治疗各种生物条件方面非常有用。
• 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
  申请人：DeLuca F. Hector

  公开号：US20080081800A1

  公开（公告）日：2008-04-03

  This invention discloses 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20R,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明披露了2-亚甲基-(20R,25S)-19,27-二去氢-(22E)-维生素D类似物，具体包括2-亚甲基-(20R,25S)-19,27-二去氢-(22E)-1α,25-二羟基维生素D3，以及其药物用途。该化合物表现出显著的活性，可阻止未分化细胞的增殖并诱导它们分化为单核细胞，因此可作为抗癌剂和治疗皮肤病例如银屑病以及皮肤状况如皱纹、松弛肌肤、干燥肌肤和皮脂分泌不足的用途。该化合物也几乎没有钙代谢活性，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨营养不良。该化合物还可用于肥胖症的治疗或预防。
• 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
  申请人：DeLuca F. Hector

  公开号：US20080081799A1

  公开（公告）日：2008-04-03

  This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明披露了2-甲烯基-(20S,25S)-19,27-二去-(22E)-维生素D类似物，特别是2-甲烯基-(20S,25S)-19,27-二去-(22E)-1α,25-二羟基维生素D3及其药物用途。该化合物表现出明显的抑制未分化细胞增殖和诱导其分化为单核细胞的活性，因此可用作抗癌剂和治疗诸如银屑病等皮肤疾病以及皮肤状况，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足。该化合物也几乎没有钙代谢活性，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨营养不良。该化合物还可用于治疗或预防肥胖症。